Phenobarbital Sodium

PreclinicalSmall molecule

UUniversity of California, San Diego

Phenobarbital Sodium is one of 11 small molecule programs targeting Neonatal seizure. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neonatal SeizureActive, not recruiting

Alcohol WithdrawalActive, not recruiting

Neonatal SeizurePreclinical

Active, not recruiting

Alcohol WithdrawalPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Alcohol Withdrawal

#DrugCompanyPhaseTrials

Lioresal

Novartis

Approved

5 2

Xyrem

Jazz Pharmaceuticals

Approved

1 3

Ativan

BBausch Health Americas, Inc.

Approved

7 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

4 5

Minipress

Pfizer

Approved

—6

Ketalar

AAultman Health Foundation

Approved

2 7

Epsom Salt

FFresenius Kabi USA, LLC

Pitocin

Serax

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 10

Luminal

Sun Pharmaceutical Industries, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Neonatal Seizure

NCT05610085

Clinical

Trials by Indication[1]

Neonatal seizure4 trials

Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital.

Completed·HHayat Abad Medical Complex, Peshawar·N/A·NCT07401433·260 enrolled

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

Recruiting·UUniversity of California, San Diego·Phase 2·NCT05610085·133 enrolled

Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures

Terminated·NNEMA Research, Inc.·Phase 3·NCT04320940·4 enrolled

Show 1 more trial

Study to Evaluate Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures

Withdrawn·PPharPoint Research, Inc.·Phase 3·NCT03602118

Brain Injury1 trial

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT06081283·5 enrolled

Alcohol Withdrawal1 trial

Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome

Terminated·UUnity Health Toronto·N/A·NCT03586089·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Phenobarbital Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phenobarbital Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phenobarbital Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Diego company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, San Diego

Phenobarbital Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Neonatal seizure4 trials

Brain Injury1 trial

Alcohol Withdrawal1 trial

References

Drug Info

Quick Facts

Related News